These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9777746)

  • 21. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
    Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
    Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine therapy in Graves' disease: is it possible to predict outcome before therapy?
    Isgoren S; Daglioz Gorur G; Demir H; Berk F
    Nucl Med Commun; 2012 Aug; 33(8):859-63. PubMed ID: 22669051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
    Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
    Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthyroid Graves' disease without detectable thyrotropin receptor antibodies.
    Ilicki A; Gamstedt A; Karlsson FA
    J Clin Endocrinol Metab; 1992 May; 74(5):1090-4. PubMed ID: 1349025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
    Gamstedt A; Karlsson A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial hyperplasia and decreased colloid content of the thyroid gland in triiodothyronine-predominant Graves' disease.
    Takamatsu J; Takeda K; Katayama S; Sakane S; Morita S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1145-50. PubMed ID: 1400885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Sonographic Features of the Thyroid Gland After Treatment with Radioiodine Therapy in Patients with Graves' Disease.
    English C; Casey R; Bell M; Bergin D; Murphy J
    Ultrasound Med Biol; 2016 Jan; 42(1):60-7. PubMed ID: 26603660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.
    Reinfelder J; Maschauer S; Foss CA; Nimmagadda S; Fremont V; Wolf V; Weintraub BD; Pomper MG; Szkudlinski MW; Kuwert T; Prante O
    Thyroid; 2011 Jul; 21(7):783-92. PubMed ID: 21568725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography.
    Crawford DC; Flower MA; Pratt BE; Hill C; Zweit J; McCready VR; Harmer CL
    Eur J Nucl Med; 1997 Dec; 24(12):1470-8. PubMed ID: 9391181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?
    Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C
    Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of TSH on iodine metabolism and intermediary metabolism in tissue from patients with Graves' disease.
    Field JB; Larsen PR; Yamashita K; Chayoth R
    J Clin Endocrinol Metab; 1974 Nov; 39(5):942-9. PubMed ID: 4370784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.